Put Options

19 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.3 - $64.42 $477,090 - $599,106
9,300 Added 155.0%
15,300 $875,000
Q2 2024

Aug 14, 2024

SELL
$37.81 - $52.4 $68,058 - $94,320
-1,800 Reduced 23.08%
6,000 $314,000
Q1 2024

May 15, 2024

SELL
$33.68 - $41.95 $127,984 - $159,410
-3,800 Reduced 32.76%
7,800 $317,000
Q4 2023

Feb 14, 2024

BUY
$33.32 - $42.1 $109,956 - $138,930
3,300 Added 39.76%
11,600 $428,000
Q3 2023

Nov 15, 2023

BUY
$36.46 - $44.03 $302,618 - $365,449
8,300 New
8,300 $317,000
Q1 2023

May 15, 2023

BUY
$32.86 - $55.7 $483,042 - $818,790
14,700 New
14,700 $548,000
Q4 2021

Feb 14, 2022

BUY
$31.82 - $40.75 $41,366 - $52,975
1,300 Added 18.84%
8,200 $331,000
Q2 2021

Aug 06, 2021

SELL
$38.84 - $51.31 $299,068 - $395,087
-7,700 Reduced 52.74%
6,900 $316,000
Q3 2020

Nov 13, 2020

SELL
$25.74 - $29.63 $7,721 - $8,889
-300 Reduced 2.01%
14,600 $387,000
Q2 2020

Aug 13, 2020

SELL
$16.25 - $26.81 $8,125 - $13,405
-500 Reduced 3.25%
14,900 $385,000
Q1 2020

May 11, 2020

BUY
$13.9 - $21.83 $22,240 - $34,928
1,600 Added 11.59%
15,400 $280,000
Q4 2019

Feb 12, 2020

BUY
$14.93 - $19.53 $46,283 - $60,543
3,100 Added 28.97%
13,800 $246,000
Q3 2019

Nov 14, 2019

SELL
$15.2 - $17.69 $9,120 - $10,614
-600 Reduced 5.31%
10,700 $163,000
Q1 2019

May 15, 2019

SELL
$13.94 - $17.58 $121,278 - $152,945
-8,700 Reduced 43.5%
11,300 $182,000
Q4 2018

Feb 14, 2019

SELL
$13.33 - $18.66 $25,327 - $35,454
-1,900 Reduced 8.68%
20,000 $286,000
Q3 2018

Nov 14, 2018

SELL
$16.68 - $18.41 $400,320 - $441,840
-24,000 Reduced 52.29%
21,900 $398,000
Q1 2018

May 15, 2018

SELL
$17.06 - $21.2 $774,524 - $962,480
-45,400 Reduced 49.73%
45,900 $899,000
Q4 2017

Feb 14, 2018

BUY
$16.75 - $20.8 $954,750 - $1.19 Million
57,000 Added 166.18%
91,300 $1.85 Million
Q3 2017

Nov 15, 2017

BUY
$11.76 - $17.4 $403,368 - $596,820
34,300
34,300 $596,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.35B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.